Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study

被引：0
|
作者：
Xinguang Wang
Zhaoqing Fan
Xing Wang
Yingjian He
Yiqiang Liu
Xiang Wang
Bailin Zhang
Zefei Jiang
Tao Wang
Zhigang Yu
Fei Wang
Yinhua Liu
Yanping Li
Jianguo Zhang
Bin Luo
Hongchuan Jiang
Tianfeng Wang
Yuntao Xie
Jinfeng Li
Tao Ouyang
机构：
[1] Peking University Cancer Hospital & Institute,Breast Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Peking University Cancer Hospital & Institute,Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Breast Surgical Oncology
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Oncology
[5] The Fifth Medical Center of PLA General Hospital,Department of Breast Surgery, Cheeloo College of Medicine, The Second Hospital
[6] Shandong University,Breast Disease Center
[7] Peking University First Hospital,Department of Breast Surgery, Beijing Shijitan Hospital
[8] Capital Medical University,Department of Breast Surgery
[9] The Second Hospital of Harbin Medical University,Department of General Surgery, Clinical School of Medicine, Tsinghua Changgung Hospital
[10] Tsinghua University,Department of Breast Surgery, Beijing Chao Yang Hospital
[11] Capital Medical University,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 195卷
关键词：
Neoadjuvant endocrine therapy; Breast cancer; Pathological response; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 310
页数：9
相关论文
共 50 条
  • [21] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [22] Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy
    O'Reilly, David
    Farooq, Abdul Rehman
    Selvadurai, Paul Nevins
    Sheehan, Laura
    Molan, Karen
    Krishnanivas, Bindu
    Mullen, Valerie
    Mcmahon, David
    Hadi, Danial
    Ahmed, Ahmed
    Jennings, Maeve
    Carroll, Hailey
    Chew, Sonya
    Macanovic, Bojan
    Brown, Ciara O'Hanlon
    Noonan, Sinead A.
    Reilly, Seamus O.
    Connolly, Roisin M.
    Cahir, Caitriona
    Kelly, Catherine M.
    ONCOLOGIST, 2024, 29 (10): : 842 - 849
  • [23] Methods for selection of neoadjuvant treatment with chemotherapy for patients with hormone receptor-positive and HER2-negative with early breast cancer.
    Gasol Cudos, Ariadna
    Morales Murillo, Serafin
    Tuset Der-abrain, Noemi
    Arbones Cid, Laura
    Morera Morillo, Ester
    Vilardell, Felip
    Sanchez Guzman, Douglas
    Canosa Morales, Carles
    Mele Olive, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
    Burris, H. A.
    Chan, A.
    Im, S-A
    Chia, S.
    Tripathy, D.
    Esteva, F. J.
    Campone, M.
    Bardia, A.
    Kong, O.
    Bao, W.
    Diaz-Padilla, I.
    Lorenc, K. Rodriguez
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [25] A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor-positive, HER2-negative breast cancer: FINEST study
    Chen, Li
    Li, Junjie
    Wang, Zhonghua
    Wu, Wenya
    Li, Huajun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [27] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [28] Early MRI and PET biomarkers for hormone receptor-positive/HER2-negative early-stage breast cancer in the setting of neoadjuvant endocrine therapy and neoadjuvant chemotherapy in the I-SPY 2 TRIAL
    Onishi, Natsuko
    Jones, Ella F.
    Carmona-Bozo, Julia
    Gibbs, Jessica E.
    Bareng, Teffany Joy
    Molina-Vega, Julissa
    Ray, Kimberly M.
    Heath, Courtney Lawhn
    Joe, Bonnie N.
    Li, Wen
    Liang, Jiachao
    Newitt, David C.
    Heditsian, Diane
    Brain, Susie
    Wolf, Denise M.
    Yau, Christina
    Giridhar, Karthik V.
    Olopade, Olufunmilayo I.
    Kalinsky, Kevin
    Mukhtar, Rita
    Esserman, Laura J.
    Chien, Jo
    Hylton, Nola M.
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [30] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
12345